Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

News Conference News ACC 2016

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

L.A. McKeown

April 04, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

News Conference News ACC 2016

When Chosen Wisely, 90-Year-Olds Do Well After TAVR

Caitlin E. Cox

April 02, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Shelley Wood

April 02, 2016

News Conference News ACC 2015

ACC-i2 2015: Strategies to Enhance PCI Results, TAVR Highlighted

Todd Neale

March 20, 2015

News Conference News ACC 2015

TVT Registry: MitraClip Holds Up Well in Early US Commercial Experience

L.A. McKeown

March 17, 2015

News Conference News ACC 2015

BEST: Due to Less TVR, CABG Still Favored Over PCI in Patients with Multivessel Disease

L.A. McKeown

March 16, 2015

Presentation ACC 2015

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

Presenter: Michael J. Mack

March 15, 2015

News Conference News ACC 2015

Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR

Yael L. Maxwell

March 15, 2015

News Conference News ACC 2015

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Todd Neale

March 15, 2015

News Conference News ACC 2014

CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks

L.A. McKeown

March 31, 2014

News Conference News ACC 2014

TAVR With the CoreValve Device Superior to Surgery at 1 Year

Yael L. Maxwell

March 29, 2014

News Conference News ACC 2013

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

L.A. McKeown

March 14, 2013

Presentation ACC 2013

Clinical Implications of New Left Bundle Branch Block: Sub-Analysis from The PARTNER Experience

Presenter: Tamim Nazif

March 11, 2013

Presentation ACC 2013

New Data from the PARTNER Non-Randomized Continued Access Registry: Outcomes After Transfemoral Transcatheter Aortic Valve Replacement

Presenter: William F. Fearon

March 11, 2013

Presentation ACC 2013

Impact of Sex on Outcomes Following Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis: Insights From The PARTNER Experience

Presenter: Ajay J. Kirtane

March 11, 2013

News Conference News ACC 2013

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

Yael L. Maxwell

March 11, 2013

Presentation ACC 2013

A Randomized Evaluation of the SAPIEN XT Transcatheter Valve System in Patients with Aortic Stenosis Who Are Not Candidates for Surgery: PARTNER II, Inoperable Cohort

Presenter: Martin B. Leon

March 09, 2013

News Conference News ACC 2013

PARTNER II Cohort B Demonstrates Safety, Efficacy of Lower Profile TAVR Device

L.A. McKeown

March 09, 2013

Advertisement

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

When Chosen Wisely, 90-Year-Olds Do Well After TAVR

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

ACC-i2 2015: Strategies to Enhance PCI Results, TAVR Highlighted

TVT Registry: MitraClip Holds Up Well in Early US Commercial Experience

BEST: Due to Less TVR, CABG Still Favored Over PCI in Patients with Multivessel Disease

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks

TAVR With the CoreValve Device Superior to Surgery at 1 Year

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

Clinical Implications of New Left Bundle Branch Block: Sub-Analysis from The PARTNER Experience

New Data from the PARTNER Non-Randomized Continued Access Registry: Outcomes After Transfemoral Transcatheter Aortic Valve Replacement

Impact of Sex on Outcomes Following Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis: Insights From The PARTNER Experience

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

A Randomized Evaluation of the SAPIEN XT Transcatheter Valve System in Patients with Aortic Stenosis Who Are Not Candidates for Surgery: PARTNER II, Inoperable Cohort

PARTNER II Cohort B Demonstrates Safety, Efficacy of Lower Profile TAVR Device

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content